Opinion|Videos|March 13, 2024
Emicizumab Dosing: Prophylaxis and Bleeding Management
An expert explains the unique dosing considerations for emicizumab compared to factor VIII in hemophilia A, covering prophylaxis and breakthrough bleeding scenarios.
Episodes in this series
This is a video synopsis/summary of an Insights featuring Steven W. Pipe, MD.
Steven W. Pipe discusses the distinctive dosing aspects of emicizumab compared to factor VIII therapies in treating hemophilia A. Addressing the historical challenge of interpatient variability in factor replacement therapy, Pipe explores the potential paradigm shift offered by emicizumab, with reduced variability noted in clinical trials. Unlike the intricate individualization required for factor VIII, emicizumab's steady-state levels diminish the need for extensive dose adjustments. While there's room for dose intensification in specific cases, emicizumab generally shows consistent efficacy across dosing regimens. In managing breakthrough bleeds, a novel aspect arises as patients now have 2 distinct treatment platforms. Emicizumab serves as prophylaxis, but for breakthrough bleeding or surgical interventions, patients revert to factor replacement therapy. Pipe emphasizes the safety of combining factor replacement with emicizumab, reassuring that clotting risks remain unaffected. Surgical interventions under emicizumab prophylaxis offer a unique advantage, allowing a potential reduction in postoperative factor replacement needs. The discussion provides valuable insights into navigating the dosing intricacies of emicizumab, highlighting its distinct approach in both prophylactic and on-demand scenarios, ultimately contributing to a comprehensive understanding of this evolving hemophilia A therapy.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Related to this article
At a Stakeholder Interchange convened by The American Journal of Managed Care® in Tampa, Florida, an academic-community mix of hematologist-oncologists and pharmacists debated prior authorization, site-of-care payment disparities, and how aggressively to push bispecific antibody regimens to community practices treating patients with relapsed/refractory multiple myeloma.
Portuguese patch testing finds many chronic hand eczema cases link to allergic contact dermatitis—especially occupational exposures like methylisothiazolinone, HEMA acrylates, thiuram mix, nickel.
The National Comprehensive Cancer Network update on mantle cell lymphoma puts covalent BTK inhibitors, MRD testing, and TP53 sequencing at the center of frontline care, while adding pirtobrutinib and a pair of CAR T-cell therapies for disease that progresses on a BTK inhibitor.
These findings demonstrate substantial but variable use of community care consultations for specialty care among patients with diabetic foot ulcers within the Veterans Health Administration.
Two posters report 3.9% first-year GLP-1 discontinuation and a 5-day median time to first fill under pharmacist-led care.
CDC's Jane Henley, MSPH, explains what's behind falling lung cancer deaths and why 4 in 5 eligible adults still aren't getting screened.
The regulatory decisions reflect how advances in biomarkers and molecular medicine are reshaping both diagnosis and treatment.
Measles cases hit a year high. Here's what payers need to know about outbreak costs, MMR coverage, and plans to split the vaccine
Trending on AJMC
1
NCCN Journal Publishes Guidelines Update in Mantle Cell Lymphoma
2
Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote
3
Switching to Subcutaneous Ocrelizumab for MS Could Free 883 Chair Hours in a Year
4
Why 4 in 5 Eligible Adults Miss Lung Cancer Screening
5